JP2012530253A - ペルオキシレドキシン４の診断的使用 - Google Patents
ペルオキシレドキシン４の診断的使用 Download PDFInfo
- Publication number
- JP2012530253A JP2012530253A JP2012515467A JP2012515467A JP2012530253A JP 2012530253 A JP2012530253 A JP 2012530253A JP 2012515467 A JP2012515467 A JP 2012515467A JP 2012515467 A JP2012515467 A JP 2012515467A JP 2012530253 A JP2012530253 A JP 2012530253A
- Authority
- JP
- Japan
- Prior art keywords
- prx4
- disease
- sample
- antibody
- clinical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000007456 Peroxiredoxin Human genes 0.000 title claims abstract description 186
- 108030002458 peroxiredoxin Proteins 0.000 title claims abstract description 186
- 201000010099 disease Diseases 0.000 claims abstract description 67
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 67
- 238000000034 method Methods 0.000 claims abstract description 53
- 239000012634 fragment Substances 0.000 claims abstract description 39
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 13
- 210000001124 body fluid Anatomy 0.000 claims abstract description 12
- 239000010839 body fluid Substances 0.000 claims abstract description 9
- 239000000523 sample Substances 0.000 claims description 88
- 210000002966 serum Anatomy 0.000 claims description 45
- 210000002381 plasma Anatomy 0.000 claims description 33
- 238000003745 diagnosis Methods 0.000 claims description 32
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 28
- 238000005259 measurement Methods 0.000 claims description 28
- 238000004393 prognosis Methods 0.000 claims description 28
- 206010040047 Sepsis Diseases 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 25
- 208000024891 symptom Diseases 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 238000013517 stratification Methods 0.000 claims description 20
- 238000003018 immunoassay Methods 0.000 claims description 17
- 206010033645 Pancreatitis Diseases 0.000 claims description 15
- 239000011230 binding agent Substances 0.000 claims description 14
- 239000000284 extract Substances 0.000 claims description 14
- 208000017169 kidney disease Diseases 0.000 claims description 13
- 238000012544 monitoring process Methods 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 206010012601 diabetes mellitus Diseases 0.000 claims description 11
- 208000019622 heart disease Diseases 0.000 claims description 11
- 230000004770 neurodegeneration Effects 0.000 claims description 11
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 239000003638 chemical reducing agent Substances 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 9
- 230000036542 oxidative stress Effects 0.000 claims description 8
- 238000003748 differential diagnosis Methods 0.000 claims description 7
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 6
- 230000009260 cross reactivity Effects 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 5
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 4
- 208000010643 digestive system disease Diseases 0.000 claims description 4
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 230000003449 preventive effect Effects 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 2
- 230000035487 diastolic blood pressure Effects 0.000 claims description 2
- 230000000391 smoking effect Effects 0.000 claims description 2
- 239000013068 control sample Substances 0.000 claims 1
- 230000035488 systolic blood pressure Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 description 65
- 239000003550 marker Substances 0.000 description 27
- 108090000765 processed proteins & peptides Proteins 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 18
- 230000035945 sensitivity Effects 0.000 description 16
- 239000000975 dye Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 102100022239 Peroxiredoxin-6 Human genes 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000011534 incubation Methods 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000012131 assay buffer Substances 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 9
- 150000002978 peroxides Chemical class 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 8
- 206010040070 Septic Shock Diseases 0.000 description 7
- 239000012491 analyte Substances 0.000 description 7
- 238000002372 labelling Methods 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 230000036303 septic shock Effects 0.000 description 7
- 241001494479 Pecora Species 0.000 description 6
- 101150083317 Shox2 gene Proteins 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 229940040511 liver extract Drugs 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 101150067974 prx3 gene Proteins 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 101100084474 Gallus gallus PRRX1 gene Proteins 0.000 description 5
- 206010018910 Haemolysis Diseases 0.000 description 5
- 101150081137 PRX1 gene Proteins 0.000 description 5
- 108010048233 Procalcitonin Proteins 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- 101100194320 Zea mays PER1 gene Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 230000008588 hemolysis Effects 0.000 description 5
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000003642 reactive oxygen metabolite Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 101001069723 Homo sapiens Paired mesoderm homeobox protein 2 Proteins 0.000 description 4
- 101001090065 Homo sapiens Peroxiredoxin-2 Proteins 0.000 description 4
- 102000003992 Peroxidases Human genes 0.000 description 4
- 102100034763 Peroxiredoxin-2 Human genes 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000006073 displacement reaction Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 4
- 238000002825 functional assay Methods 0.000 description 4
- 229910000160 potassium phosphate Inorganic materials 0.000 description 4
- 235000011009 potassium phosphates Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000001542 size-exclusion chromatography Methods 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102000003945 NF-kappa B Human genes 0.000 description 3
- 108010057466 NF-kappa B Proteins 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 206010033647 Pancreatitis acute Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 201000003229 acute pancreatitis Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- -1 lipid hydroperoxide Chemical class 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010007556 Cardiac failure acute Diseases 0.000 description 2
- 206010007558 Cardiac failure chronic Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101100191630 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) prxA gene Proteins 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 102000004722 NADPH Oxidases Human genes 0.000 description 2
- 108010002998 NADPH Oxidases Proteins 0.000 description 2
- 101100245232 Penicillium rubens (strain ATCC 28089 / DSM 1075 / NRRL 1951 / Wisconsin 54-1255) prx5 gene Proteins 0.000 description 2
- 101100245235 Penicillium rubens (strain ATCC 28089 / DSM 1075 / NRRL 1951 / Wisconsin 54-1255) prx6 gene Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- FXIRVRPOOYSARH-REOHCLBHSA-N S-hydroxy-L-cysteine Chemical compound OC(=O)[C@@H](N)CSO FXIRVRPOOYSARH-REOHCLBHSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000002967 competitive immunoassay Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 150000002019 disulfides Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000813 peptide hormone Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 229910052761 rare earth metal Inorganic materials 0.000 description 2
- 150000002910 rare earth metals Chemical class 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012502 risk assessment Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000005222 synovial tissue Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- IDLISIVVYLGCKO-UHFFFAOYSA-N 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein Chemical compound O1C(=O)C2=CC=C(C(O)=O)C=C2C21C1=CC(OC)=C(O)C(Cl)=C1OC1=C2C=C(OC)C(O)=C1Cl IDLISIVVYLGCKO-UHFFFAOYSA-N 0.000 description 1
- WQZIDRAQTRIQDX-UHFFFAOYSA-N 6-carboxy-x-rhodamine Chemical compound OC(=O)C1=CC=C(C([O-])=O)C=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 WQZIDRAQTRIQDX-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- VWOLRKMFAJUZGM-UHFFFAOYSA-N 6-carboxyrhodamine 6G Chemical compound [Cl-].C=12C=C(C)C(NCC)=CC2=[O+]C=2C=C(NCC)C(C)=CC=2C=1C1=CC(C(O)=O)=CC=C1C(=O)OCC VWOLRKMFAJUZGM-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 1
- 101001024703 Homo sapiens Nck-associated protein 5 Proteins 0.000 description 1
- 101100137540 Homo sapiens PRX gene Proteins 0.000 description 1
- 101001069727 Homo sapiens Paired mesoderm homeobox protein 1 Proteins 0.000 description 1
- 101001090047 Homo sapiens Peroxiredoxin-4 Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100036946 Nck-associated protein 5 Human genes 0.000 description 1
- 101150105986 PEX4 gene Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 101710167005 Thiol:disulfide interchange protein DsbD Proteins 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-O acridine;hydron Chemical compound C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-O 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 102000044468 human PRDX4 Human genes 0.000 description 1
- 102000050557 human PRRX1 Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000011545 laboratory measurement Methods 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- ZBJWWKFMHOAPNS-UHFFFAOYSA-N loretin Chemical compound C1=CN=C2C(O)=C(I)C=C(S(O)(=O)=O)C2=C1 ZBJWWKFMHOAPNS-UHFFFAOYSA-N 0.000 description 1
- 229950010248 loretin Drugs 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000004963 pathophysiological condition Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 150000005053 phenanthridines Chemical class 0.000 description 1
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- MYIOYATURDILJN-UHFFFAOYSA-N rhodamine 110 Chemical compound [Cl-].C=12C=CC(N)=CC2=[O+]C2=CC(N)=CC=C2C=1C1=CC=CC=C1C(O)=O MYIOYATURDILJN-UHFFFAOYSA-N 0.000 description 1
- 230000009991 second messenger activation Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- BUUPQKDIAURBJP-UHFFFAOYSA-N sulfinic acid Chemical compound OS=O BUUPQKDIAURBJP-UHFFFAOYSA-N 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/908—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09162874 | 2009-06-16 | ||
| EP09162874.3 | 2009-06-16 | ||
| EP09167940 | 2009-08-14 | ||
| EP09167940.7 | 2009-08-14 | ||
| PCT/EP2010/058414 WO2010146064A1 (en) | 2009-06-16 | 2010-06-15 | Diagnostical use of peroxiredoxin 4 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012530253A true JP2012530253A (ja) | 2012-11-29 |
| JP2012530253A5 JP2012530253A5 (enExample) | 2013-01-17 |
Family
ID=42357554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012515467A Pending JP2012530253A (ja) | 2009-06-16 | 2010-06-15 | ペルオキシレドキシン４の診断的使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20120129187A1 (enExample) |
| EP (1) | EP2443148A1 (enExample) |
| JP (1) | JP2012530253A (enExample) |
| CN (1) | CN102482343A (enExample) |
| WO (1) | WO2010146064A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011206049A (ja) | 2010-03-08 | 2011-10-20 | Sumio Sugano | 壊死マーカー及びその用途 |
| CN102346190A (zh) * | 2011-01-24 | 2012-02-08 | 中国人民解放军第三军医大学 | 用于检测生物标本中的过氧化物还原酶ⅳ的双抗夹心elisa试剂盒及其方法与运用 |
| CN102344916B (zh) * | 2011-01-24 | 2013-08-07 | 中国人民解放军第三军医大学 | 类风湿关节炎特异性抗原 |
| CN102346186B (zh) * | 2011-01-24 | 2015-05-27 | 中国人民解放军第三军医大学 | 用于检测生物标本中的过氧化物还原酶ⅳ抗体的elisa试剂盒及其方法与运用 |
| CN103308674B (zh) * | 2012-12-20 | 2018-04-06 | 周继蓉 | 过氧化物还原酶iv的循环免疫复合物及其应用 |
| EP3132268B1 (en) * | 2014-04-15 | 2019-10-16 | Cézanne S.A.S. | Immunoassay for the detection of chromogranin a |
| CN106093429A (zh) * | 2016-06-02 | 2016-11-09 | 滨州医学院 | 一种检测胃癌组织的试剂盒 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020106323A1 (en) * | 1995-06-06 | 2002-08-08 | Jian Ni | Natural killer cell enhancing factor C |
| WO2004055519A2 (en) * | 2002-12-17 | 2004-07-01 | Sinogenomax Co. Ltd. | Specific markers for pancreatic cancer |
| JP2005080524A (ja) * | 2003-09-05 | 2005-03-31 | Japan Science & Technology Agency | 前立腺癌マーカポリペプチド、該ポリペプチドに対する抗体、及び該ポリペプチドを利用した前立腺癌の診断方法 |
| JP2007192746A (ja) * | 2006-01-20 | 2007-08-02 | Keio Gijuku | 酸化ストレスの判定方法 |
| WO2007123507A1 (en) * | 2006-03-20 | 2007-11-01 | Inverness Medical Switzerland Gmbh | Water-soluble conjugates for electrochemical detection |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5501969A (en) * | 1994-03-08 | 1996-03-26 | Human Genome Sciences, Inc. | Human osteoclast-derived cathepsin |
| US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| DE10316583A1 (de) | 2003-04-10 | 2004-10-28 | B.R.A.H.M.S Aktiengesellschaft | Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung |
| EP1628136A1 (en) | 2004-08-19 | 2006-02-22 | B.R.A.H.M.S. Aktiengesellschaft | Method of diagnosis of disease using copeptin |
| WO2007140352A2 (en) * | 2006-05-26 | 2007-12-06 | Invitrogen Corporation | Plasma membrane and secreted cancer biomarkers |
-
2010
- 2010-06-15 WO PCT/EP2010/058414 patent/WO2010146064A1/en not_active Ceased
- 2010-06-15 JP JP2012515467A patent/JP2012530253A/ja active Pending
- 2010-06-15 CN CN2010800265623A patent/CN102482343A/zh active Pending
- 2010-06-15 US US13/378,460 patent/US20120129187A1/en not_active Abandoned
- 2010-06-15 EP EP10727712A patent/EP2443148A1/en not_active Withdrawn
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020106323A1 (en) * | 1995-06-06 | 2002-08-08 | Jian Ni | Natural killer cell enhancing factor C |
| WO2004055519A2 (en) * | 2002-12-17 | 2004-07-01 | Sinogenomax Co. Ltd. | Specific markers for pancreatic cancer |
| JP2005080524A (ja) * | 2003-09-05 | 2005-03-31 | Japan Science & Technology Agency | 前立腺癌マーカポリペプチド、該ポリペプチドに対する抗体、及び該ポリペプチドを利用した前立腺癌の診断方法 |
| JP2007192746A (ja) * | 2006-01-20 | 2007-08-02 | Keio Gijuku | 酸化ストレスの判定方法 |
| WO2007123507A1 (en) * | 2006-03-20 | 2007-11-01 | Inverness Medical Switzerland Gmbh | Water-soluble conjugates for electrochemical detection |
| JP2009530639A (ja) * | 2006-03-20 | 2009-08-27 | インバーネス・メデイカル・スウイツツアーランド・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | 電気化学的検出のための水溶性コンジュゲート |
Non-Patent Citations (1)
| Title |
|---|
| JPN5012014939; ＣＨＡＮＧ Ｘ: 'ＩＤＥＮＴＩＦＩＣＡＴＩＯＮ ＯＦ ＰＲＯＴＥＩＮＳ ＷＩＴＨ ＩＮＣＲＥＡＳＥＥＤ ＥＸＰＲＥＳＳＩＯＮ ＩＮ ＲＨＥＵＭＡＴＯＩＤ ＡＲＴＨＲＩＴＩＳ ＳＹＮＯＶＩＡＬ ＴＩＳＳＵＥＳ' ＪＯＵＲＮＡＬ ＯＦ ＰＨＥＵＭＡＴＯＬＯＧＹ Ｖ３６ Ｎ５, 20090501, Ｐ８７２-８８０, ＪＯＵＲＮＡＬ ＯＦ ＰＨＥＵＭＡＴＯＬＯＧＹ ＰＵＢＬＩＳＨＩＮＧ ＣＯＭＰＡＮＹ * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010146064A1 (en) | 2010-12-23 |
| CN102482343A (zh) | 2012-05-30 |
| EP2443148A1 (en) | 2012-04-25 |
| US20120129187A1 (en) | 2012-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2353011B1 (en) | Biomarker for the prediction of first adverse events | |
| JP2012530253A (ja) | ペルオキシレドキシン４の診断的使用 | |
| US20230097988A1 (en) | Methods for determining peptidylglycine alpha-amidating monooxygenase (pam) and its use for diagnostic purpose | |
| US20110039276A1 (en) | Identifying organ damage | |
| US20050014198A1 (en) | Assays and kits for detecting and monitoring heart disease | |
| CA2814026C (en) | Moesin fragments associated with aplastic anemia | |
| US9347950B2 (en) | Moesin fragments associated with immune thrombocytopenia | |
| EA034364B1 (ru) | Иммуноанализ для обнаружения хромогранина а | |
| CN110678757B (zh) | 诊断或监测肾功能或诊断肾功能障碍的方法 | |
| CA2748852C (en) | Biomarkers associated with nephropathy | |
| CN111542755A (zh) | 用于预测第一次心血管事件的硒蛋白p | |
| CN104330570B (zh) | 人热休克蛋白gp96在制备筛查肝病的产品中的应用 | |
| WO2012101246A1 (en) | Methods and means for diagnosing vasculitis | |
| JP5120843B2 (ja) | 自己免疫性膵炎の検査方法及び検査試薬 | |
| JP5413863B2 (ja) | 劇症１型糖尿病の検査方法及び検査試薬 | |
| EP2707495B1 (en) | Biochemical markers for cvd risk assessment | |
| HK1169122A (en) | Diagnostical use of peroxiredoxin 4 | |
| US20110201947A1 (en) | Oxidized paraoxonase 1 and paraoxonase 1/hdl particle number ratio as risk markers for cardiovascular disease | |
| US8841084B2 (en) | Methods for the detection and monitoring of acute myocardial infarction | |
| JP2024039982A (ja) | 急性腎障害の発症リスクの評価方法 | |
| CN119661680A (zh) | 心肌肌钙蛋白i片段及用其制备的产品和应用 | |
| HK40016117A (en) | A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction | |
| HK1244314A1 (zh) | 一种预测受试者的肥胖风险的方法 | |
| HK40033912A (en) | Selenoprotein p for prediction of a first cardiovascular event | |
| WO2000063238A1 (en) | Nonextractive method of assaying thymopoietin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121113 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20121113 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131022 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20131023 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140115 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140122 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140819 |